UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Molecular profiling for precision cancer therapies

Genome medicine, 2020-01, Vol.12 (1), p.8-8, Article 8

2020

Volltextzugriff (PDF)

Circulating tumor DNA and liquid biopsy in oncology

Nature cancer, 2020-03, Vol.1 (3), p.276-290

2020

Volltextzugriff (PDF)

Dose Escalation Methods in Phase I Cancer Clinical Trials

JNCI : Journal of the National Cancer Institute, 2009-05, Vol.101 (10), p.708-720

2009

Volltextzugriff (PDF)

Designing Transformative Clinical Trials in the Cancer Genome Era

Journal of clinical oncology, 2013-05, Vol.31 (15), p.1834-1841

2013

Volltextzugriff (PDF)

Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment

BMC medicine, 2012-12, Vol.10 (1), p.161-161, Article 161

2012

Volltextzugriff (PDF)

Approaches to modernize the combination drug development paradigm

Genome medicine, 2016-10, Vol.8 (1), p.115-115, Article 115

2016

Volltextzugriff (PDF)

Deintensification Candidate Subgroups in Human Papillomavirus–Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis

Journal of clinical oncology, 2013-02, Vol.31 (5), p.543-550

2013

Volltextzugriff (PDF)

Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline

Journal of clinical oncology, 2017-05, Vol.35 (14), p.1606-1621

2017

Volltextzugriff (PDF)

Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study

Clinical cancer research, 2020-10, Vol.26 (19), p.5153-5161

2020

Volltextzugriff (PDF)

Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era

European journal of cancer (1990), 2021-11, Vol.158, p.85-98

2021

Volltextzugriff (PDF)

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

Journal of clinical oncology, 2012-08, Vol.30 (23), p.2919-2928

2012

Volltextzugriff (PDF)

First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting

Journal of hematology & oncology, 2008-10, Vol.1 (1), p.20-20, Article 20

2008

Volltextzugriff (PDF)

Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy

PloS one, 2021-06, Vol.16 (6), p.e0253070

2021

Volltextzugriff (PDF)

Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials

Frontiers in oncology, 2019-05, Vol.9, p.415-415

2019

Volltextzugriff (PDF)

Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma

Clinical cancer research, 2021-08, Vol.27 (15), p.4230-4244

2021

Volltextzugriff (PDF)

Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis

European journal of cancer (1990), 2015-08, Vol.51 (12), p.1570-1579

2015

Volltextzugriff (PDF)

Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials

JNCI : Journal of the National Cancer Institute, 2021-08, Vol.113 (8), p.980-988

2021

Volltextzugriff (PDF)

Using real-word data to evaluate the effects of broadening eligibility criteria in oncology trials

Cancer cell, 2021-06, Vol.39 (6), p.750-752

2021

Volltextzugriff (PDF)

Systematic Review of Barriers to the Recruitment of Older Patients With Cancer Onto Clinical Trials

Journal of clinical oncology, 2005-05, Vol.23 (13), p.3112-3124

2005

Volltextzugriff (PDF)

Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval

Journal of clinical oncology, 2007-08, Vol.25 (22), p.3362-3371

2007

Volltextzugriff (PDF)

Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion

Journal of clinical oncology, 2019-06, Vol.37 (18), p.1578-1589

2019

Volltextzugriff (PDF)

Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies

Clinical cancer research, 2017-09, Vol.23 (17), p.4950-4958

2017

Volltextzugriff (PDF)

Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors

Journal of clinical oncology, 2012-05, Vol.30 (13), p.1527-1533

2012

Volltextzugriff (PDF)

Atypical Clinical Behavior of p16-Confirmed HPV-Related Oropharyngeal Squamous Cell Carcinoma Treated With Radical Radiotherapy

International journal of radiation oncology, biology, physics, 2012, Vol.82 (1), p.276-283

2012

Volltextzugriff (PDF)

Development of Fibroblast Growth Factor Receptor Inhibitors: Kissing Frogs to Find a Prince?

Journal of clinical oncology, 2015-10, Vol.33 (30), p.3372-3374

2015

Volltextzugriff (PDF)

1 – 25 von 582

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(555)
Mit Volltextzugriff
(532)

Publikationsform

Sprache

Englisch
(581)
Japanisch
(63)

Erscheinungsjahr

n.n

Thema

Science & Technology
(325)
Life Sciences & Biomedicine
(318)
Oncology
(287)
Humans
(279)
Female
(135)
Male
(135)
Middle Aged
(123)
Aged
(121)
Adult
(107)
Neoplasms - Drug Therapy
(106)
Tumors
(101)
Biological And Medical Sciences
(91)
Medical Sciences
(90)
Chemotherapy
(68)
Cancer
(67)
Clinical Trials
(62)
Treatment Outcome
(50)
Antineoplastic Agents - Therapeutic Use
(48)
Antineoplastic Agents
(47)
Patients
(47)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

Molecular profiling for precision cancer therapies

Circulating tumor DNA and liquid biopsy in oncology

Dose Escalation Methods in Phase I Cancer Clinical Trials

Designing Transformative Clinical Trials in the Cancer Genome Era

Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment

Approaches to modernize the combination drug development paradigm

Deintensification Candidate Subgroups in Human Papillomavirus–Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis

Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline

Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study

Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting

Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy

Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials

Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma

Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis

Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials

Using real-word data to evaluate the effects of broadening eligibility criteria in oncology trials

Systematic Review of Barriers to the Recruitment of Older Patients With Cancer Onto Clinical Trials

Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval

Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion

Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies

Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors

Atypical Clinical Behavior of p16-Confirmed HPV-Related Oropharyngeal Squamous Cell Carcinoma Treated With Radical Radiotherapy

Development of Fibroblast Growth Factor Receptor Inhibitors: Kissing Frogs to Find a Prince?

Suchergebnisse filtern